Valeria Bianconi

Valeria Bianconi

Auto-generated profile, based on publicly available information

Valeria Bianconi

Institute of Molecular Biology and Pathology-National Research Council (CNR), Department of Biology and Biotechnology, Sapienza University of Rome, 00185 Rome, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
BBBeatrice Biferali
Beatrice Biferali
VBValeria Bianconi
Valeria Bianconi
DPDaniel Fernandez Perez
Daniel Fernandez Perez
SKSophie Pöhle Kronawitter
Sophie Pöhle Kronawitter
FMFabrizia Marullo
Fabrizia Marullo
CMChiara Mozzetta
Chiara Mozzetta
A druggable mechanism is found to reprogram fibro-adipogenic progenitors toward myogenesis and to improve muscle repair.

5 April 2022 in Life
Verified
Journal Article
Open access
PDF file
MMMarta Morotti
Marta Morotti
SGStefano Garofalo
Stefano Garofalo
GCGermana Cocozza
Germana Cocozza
FAFabrizio Antonangeli
Fabrizio Antonangeli
VBValeria Bianconi
Valeria Bianconi
Francesca GrassiFrancesca Grassi
Francesca Grassi
Duchenne muscular dystrophy (DMD) is an X-linked disease, caused by a mutant dystrophin gene, leading to muscle membrane instability, followed by muscle inflammation, infiltration of pro-inflammatory macrophages and fibrosis. The calcium-activated potassium channel type 3.1 (KCa3.1) plays key roles in controlling both macrophage phenotype and fibroblast proliferation, two critical contributors to muscle damage. In this work, we demonstrate that pharmacological blockade of the channel in the mdx mouse model during the early degenerative phase favors the acquisition of an anti-inflammatory phenotype by tissue macrophages and reduces collagen deposition in muscles, with a concomitant reduction of muscle damage. As already observed with other treatments, no improvement in muscle performance was observed in vivo. In conclusion, this work supports the idea that KCa3.1 channels play a contributing role in controlling damage-causing cells in DMD. A more complete understanding of their function could lead to the identification of novel therapeutic approaches.